Maria S Ortiz-Urda, MD
Dermatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 7 carriers
- Offices
- 3
Offices
3 locations · University of California San Francisco · UCSF Medical Group Business Services · Roberta D Sengelmann MD Inc
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
28 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ortiz-Urda’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A105136 · Current
Licensed to practise in California · since 2008 · expires 2028-02-29 · University of Vienna Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$178,115
Medicare paid this office $178,115 for 908 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 493 | $47,131 | $64 |
| Short return visit (20+ min) | 205 | $16,808 | $55 |
| Destruction of precancer skin growth, 1 growth | 325 | $16,675 | $40 |
| Destruction of skin growth, 1-14 growths | 149 | $16,484 | $91 |
| Biopsy of related skin growth, first growth | 195 | $16,121 | $69 |
See all 20 services
| Short return visit (20+ min) | 493 | $47,131 | $64 |
| Short return visit (20+ min) | 205 | $16,808 | $55 |
| Destruction of precancer skin growth, 1 growth | 325 | $16,675 | $40 |
| Destruction of skin growth, 1-14 growths | 149 | $16,484 | $91 |
| Biopsy of related skin growth, first growth | 195 | $16,121 | $69 |
| Destruction of precancer skin growth, 15 or more growths | 52 | $9,294 | $141 |
| New patient visit (30+ min) | 120 | $8,775 | $73 |
| Destruction of precancer skin growth, 2-14 growths | 245 | $7,849 | $6 |
| Destruction of precancer skin growth, 1 growth | 119 | $6,866 | $47 |
| Destruction of skin growth, 1-14 growths | 52 | $3,620 | $61 |
| New patient visit (30+ min) | 45 | $3,001 | $67 |
| Short return visit | 60 | $2,610 | $44 |
| Biopsy of related skin growth, each additional growth | 39 | $2,558 | $44 |
| Return visit (30+ min) | 29 | $2,484 | $80 |
| Biopsy of related skin growth, first growth | 86 | $2,380 | $25 |
| Return visit (30+ min) | 18 | $1,877 | $99 |
| Destruction of precancer skin growth, 15 or more growths | 19 | $1,780 | $85 |
| Punch biopsy, first skin growth | 13 | $1,545 | $110 |
| Destruction of precancer skin growth, 2-14 growths | 94 | $849 | $2 |
| Biopsy of related skin growth, each additional growth | 18 | $376 | $20 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 1653 | More than 97% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 396 | More than 94% of doctors who do this |
Who their Medicare patients are
908 Original Medicare patients in 2024. Average age 75 · Under 65 2% · 85 and older 10% · Women 61% · Also on Medicaid 7% · Health risk score 0.96. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Coronary heart disease 18% · Cancer 18% · Depression 16% · Chronic kidney disease 15% · Diabetes 14% · Atrial fibrillation 14% · Heart failure 8% · COPD 7% · Stroke 5% · Dementia 3%.
The office billed $844,137, Medicare allowed $252,105 and paid $178,115; for 4,611 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 908 | 4,611 | 75 | 0.96 | $844,137 | $178,115 |
| 2023 | 1,272 | 6,095 | 75 | 0.90 | $934,273 | $249,456 |
| 2022 | 634 | 2,414 | 75 | 1.03 | $570,012 | $126,010 |
| 2021 | 444 | 1,788 | 73 | 1.41 | $525,746 | $61,556 |
| 2020 | 310 | 1,257 | 72 | 1.40 | $426,560 | $39,923 |
| 2019 | 340 | 1,455 | 72 | 1.31 | $443,114 | $41,121 |
| 2018 | 289 | 1,094 | 72 | 1.31 | $331,458 | $32,014 |
| 2017 | 280 | 1,013 | 71 | 1.32 | $305,748 | $33,379 |
| 2016 | 209 | 698 | 71 | 1.28 | $209,411 | $21,077 |
| 2015 | 210 | 709 | 71 | 1.14 | $208,528 | $21,219 |
| 2014 | 192 | 623 | 71 | 0.95 | $207,168 | $22,891 |
| 2013 | 122 | 435 | 71 | 1.06 | $150,992 | $19,451 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Short return visit (20+ min) | 647 | $60,933 | $68 |
| Destruction of precancer skin growth, 1 growth | 499 | $26,952 | $43 |
| Destruction of skin growth, 1-14 growths | 238 | $23,852 | $92 |
| Biopsy of related skin growth, first growth | 247 | $21,712 | $78 |
| New patient visit (30+ min) | 258 | $20,232 | $78 |
| Destruction of precancer skin growth, 2-14 growths | 390 | $12,996 | $6 |
| Short return visit (20+ min) | 185 | $12,924 | $54 |
| Destruction of precancer skin growth, 15 or more growths | 64 | $10,827 | $144 |
| Return visit (30+ min) | 96 | $9,018 | $87 |
| Short return visit | 155 | $8,234 | $46 |
| Destruction of precancer skin growth, 1 growth | 108 | $5,819 | $44 |
| New patient visit (45+ min) | 36 | $3,831 | $106 |
| Return visit (30+ min) | 36 | $2,725 | $72 |
| Destruction of skin growth, 1-14 growths | 39 | $2,550 | $58 |
| New patient visit (15+ min) | 38 | $1,960 | $52 |
| Punch biopsy, first skin growth | 17 | $1,944 | $108 |
| Biopsy of related skin growth, each additional growth | 39 | $1,941 | $46 |
| Simple or single drainage of skin abscess | 13 | $1,293 | $99 |
| New patient visit (30+ min) | 14 | $1,033 | $74 |
| Biopsy of related skin growth, first growth | 42 | $1,027 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 93 | $783 | $2 |
| Injection into skin growth, 1-7 growths | 11 | $541 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $13 | None |
2022: 20 services
| Return visit (30+ min) | 125 | $14,150 | $106 |
| Short return visit (20+ min) | 200 | $13,439 | $51 |
| Short return visit (20+ min) | 141 | $12,600 | $79 |
| New patient visit (45+ min) | 91 | $11,934 | $131 |
| Destruction of skin growth, 1-14 growths | 84 | $9,907 | $105 |
| Destruction of precancer skin growth, 1 growth | 130 | $7,428 | $51 |
| Return visit (30+ min) | 66 | $6,505 | $82 |
| Destruction of precancer skin growth, 1 growth | 129 | $6,317 | $43 |
| New patient visit (30+ min) | 58 | $5,464 | $94 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 28 | $3,397 | $121 |
| Destruction of precancer skin growth, 2-14 growths | 101 | $2,776 | $7 |
| Destruction of skin growth, 1-14 growths | 43 | $2,505 | $56 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $2,446 | $163 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 16 | $2,333 | $137 |
| Punch biopsy, first skin growth | 13 | $1,685 | $130 |
| Biopsy of related skin growth, first growth | 61 | $1,422 | $21 |
| Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | 11 | $1,152 | $105 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,116 | $80 |
| New patient visit (30+ min) | 17 | $964 | $57 |
| Destruction of precancer skin growth, 2-14 growths | 109 | $737 | $2 |
2021: 12 services
| Short return visit (20+ min) | 272 | $20,668 | $53 |
| Destruction of precancer skin growth, 1 growth | 151 | $8,005 | $43 |
| New patient visit (30+ min) | 101 | $6,847 | $68 |
| Return visit (30+ min) | 53 | $5,468 | $84 |
| Destruction of skin growth, 1-14 growths | 42 | $2,643 | $63 |
| Destruction of precancer skin growth, 15 or more growths | 24 | $2,592 | $93 |
| Short return visit (20+ min) | 28 | $2,488 | $89 |
| Biopsy of related skin growth, first growth | 67 | $1,766 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 128 | $1,182 | $2 |
| Destruction of precancer skin growth, 1 growth | 15 | $888 | $55 |
| Biopsy of related skin growth, each additional growth | 14 | $301 | $18 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $288 | $7 |
2020: 11 services
| Short return visit (20+ min) | 235 | $15,015 | $41 |
| Destruction of precancer skin growth, 1 growth | 100 | $5,751 | $46 |
| New patient visit (30+ min) | 60 | $3,983 | $66 |
| Destruction of precancer skin growth, 15 or more growths | 29 | $3,195 | $91 |
| Destruction of skin growth, 1-14 growths | 37 | $2,363 | $62 |
| Biopsy of related skin growth, first growth | 63 | $1,860 | $26 |
| New patient visit (15+ min) | 27 | $1,061 | $39 |
| Return visit (30+ min) | 12 | $867 | $72 |
| Destruction of precancer skin growth, 2-14 growths | 83 | $785 | $2 |
| Punch biopsy, first skin growth | 19 | $711 | $37 |
| Biopsy of related skin growth, each additional growth | 21 | $676 | $20 |
2019: 10 services
| Short return visit (20+ min) | 272 | $17,607 | $41 |
| Destruction of precancer skin growth, 1 growth | 129 | $7,341 | $44 |
| Destruction of skin growth, 1-14 growths | 44 | $2,993 | $60 |
| Destruction of precancer skin growth, 15 or more growths | 25 | $2,646 | $85 |
| New patient visit (30+ min) | 39 | $2,526 | $65 |
| Biopsy of related skin growth, first growth | 70 | $1,888 | $26 |
| New patient visit (15+ min) | 46 | $1,831 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 105 | $1,099 | $2 |
| Punch biopsy, first skin growth | 15 | $638 | $40 |
| Biopsy of related skin growth, each additional growth | 11 | $327 | $20 |
2018: 7 services
| Short return visit (20+ min) | 236 | $14,870 | $41 |
| Destruction of precancer skin growth, 1 growth | 108 | $5,959 | $44 |
| New patient visit (30+ min) | 44 | $2,873 | $65 |
| Destruction of skin growth, 1-14 growths | 39 | $2,394 | $60 |
| Biopsy of single growth of skin and/or tissue | 64 | $2,380 | $34 |
| New patient visit (15+ min) | 22 | $827 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 85 | $734 | $2 |
2017: 8 services
| Short return visit (20+ min) | 236 | $16,320 | $43 |
| Destruction of precancer skin growth, 1 growth | 99 | $5,255 | $45 |
| Destruction of skin growth, 1-14 growths | 44 | $3,220 | $69 |
| New patient visit (30+ min) | 42 | $2,848 | $68 |
| Biopsy of single growth of skin and/or tissue | 51 | $2,220 | $38 |
| New patient visit (15+ min) | 20 | $859 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 79 | $632 | $2 |
| Short return visit | 12 | $295 | $23 |
2016: 8 services
| Short return visit (20+ min) | 185 | $12,306 | $40 |
| Destruction of precancer skin growth, 1 growth | 58 | $2,859 | $41 |
| Biopsy of single growth of skin and/or tissue | 47 | $2,005 | $36 |
| Destruction of skin growth, 1-14 growths | 15 | $1,167 | $65 |
| New patient visit (30+ min) | 12 | $749 | $62 |
| New patient visit (15+ min) | 19 | $641 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 49 | $348 | $2 |
| Short return visit | 13 | $311 | $21 |
2015: 8 services
| Short return visit (20+ min) | 161 | $10,162 | $40 |
| Destruction of precancer skin growth, 1 growth | 56 | $2,935 | $41 |
| New patient visit (30+ min) | 32 | $1,938 | $61 |
| Biopsy of single growth of skin and/or tissue | 42 | $1,650 | $37 |
| Destruction of skin growth, 1-14 growths | 22 | $1,630 | $63 |
| New patient visit (15+ min) | 27 | $1,069 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 43 | $418 | $2 |
| Short return visit | 14 | $274 | $16 |
2014: 9 services
| Short return visit (20+ min) | 142 | $8,353 | $42 |
| New patient visit (45+ min) | 35 | $3,910 | $112 |
| Destruction of precancer skin growth, 1 growth | 56 | $3,161 | $45 |
| Biopsy of single growth of skin and/or tissue | 44 | $1,799 | $37 |
| New patient visit (30+ min) | 18 | $1,112 | $62 |
| Destruction of skin growth, 1-14 growths | 14 | $1,011 | $67 |
| Return visit (30+ min) | 17 | $986 | $55 |
| New patient visit (15+ min) | 11 | $449 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 43 | $332 | $2 |
2013: 7 services
| Return visit (30+ min) | 87 | $8,257 | $64 |
| New patient visit (45+ min) | 41 | $4,593 | $112 |
| Destruction of precancer skin growth, 1 growth | 38 | $2,099 | $46 |
| Biopsy of single growth of skin and/or tissue | 39 | $1,596 | $36 |
| Destruction of skin growth, 1-14 growths | 11 | $763 | $69 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $441 | $3 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $401 | $20 |
Medicaid work
$1,811 in 2024
Medicaid paid $1,811 for 22 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 22 | $1,811 |
| 2024 | 22 | 1 | 22 | $1,811 |
| 2023 | 14 | 1 | 14 | $965 |
| 2022 | 52 | 3 | 14 | $0 |
See the largest Medicaid services in earlier years
2023
| New patient visit (30+ min) | 14 | $965 |
2022
| New patient visit (30+ min) | 12 | $0 |
| New patient visit (45+ min) | 26 | $0 |
| Patient screened for tobacco use and identified as a tobacco non-user | 14 | $0 |
Drugs they prescribed that Part D paid
$19,458
Pharmacies billed $19,458 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 724) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
720 generic and fewer than 11 brand-name prescriptions · $19,458 in drug cost · 40 antibiotic prescriptions to 37 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 71 | $4,780 | $67 |
| Fluorouracil | 72 | $4,677 | $65 |
| Ketoconazole | 134 | $1,966 | $15 |
| Fluocinonide | 53 | $1,775 | $33 |
| Triamcinolone Acetonide | 105 | $1,251 | $12 |
See all 19 drugs
| Clobetasol Propionate | 71 | $4,780 | $67 |
| Fluorouracil | 72 | $4,677 | $65 |
| Ketoconazole | 134 | $1,966 | $15 |
| Fluocinonide | 53 | $1,775 | $33 |
| Triamcinolone Acetonide | 105 | $1,251 | $12 |
| Tretinoin | 14 | $948 | $68 |
| Permethrin | 21 | $929 | $44 |
| Metronidazole | 17 | $725 | $43 |
| Clindamycin Phosphate | 20 | $507 | $25 |
| Ivermectin | 13 | $301 | $23 |
| Doxycycline Hyclate | 25 | $222 | $9 |
| Valacyclovir | 23 | $209 | $9 |
| Ciclopirox | 11 | $190 | $17 |
| Hydrocortisone | 27 | $122 | $5 |
| Minoxidil | 16 | $82 | $5 |
| Cephalexin | 14 | $70 | $5 |
| Spironolactone | 19 | $62 | $3 |
| Prednisone | 27 | $30 | $1 |
| Gabapentin | 12 | $22 | $2 |
Year by year
| 2024 | 724 | 307 | 0% (0) | None | $19,458 |
| 2023 | 923 | 455 | 0% (0) | 2% | $67,094 |
| 2022 | 433 | 259 | 0% (0) | 3% | $23,778 |
| 2021 | 255 | 118 | 0% (0) | None | $13,100 |
| 2020 | 238 | 103 | 0% (0) | 5% | $22,595 |
| 2019 | 166 | 97 | 0% (0) | 7% | $13,040 |
| 2018 | 117 | 65 | 0% (0) | None | $5,341 |
| 2017 | 105 | 45 | 0% (0) | None | $7,718 |
| 2016 | 103 | 38 | 0% (0) | None | $9,686 |
| 2015 | 118 | 51 | 0% (0) | None | $17,639 |
| 2014 | 87 | 46 | 0% (0) | 20% | $8,314 |
| 2013 | 50 | 24 | 0% (0) | None | $3,818 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Fluorouracil | 98 | $8,504 | $87 |
| Clobetasol Propionate | 91 | $6,036 | $66 |
| Fluocinonide | 72 | $3,608 | $50 |
| Ketoconazole | 143 | $3,101 | $22 |
| Metronidazole | 35 | $2,609 | $75 |
| Triamcinolone Acetonide | 159 | $1,901 | $12 |
| Permethrin | 28 | $1,255 | $45 |
| Desonide | 15 | $922 | $61 |
| Doxycycline Hyclate | 27 | $866 | $32 |
| Clindamycin Phosphate | 17 | $575 | $34 |
| Cephalexin | 29 | $495 | $17 |
| Hydrocortisone | 46 | $466 | $10 |
| Valacyclovir | 25 | $411 | $16 |
| Ciclopirox | 16 | $349 | $22 |
| Minoxidil | 12 | $181 | $15 |
2022: 8 drugs
| Fluorouracil | 50 | $5,048 | $101 |
| Clobetasol Propionate | 36 | $3,920 | $109 |
| Metronidazole | 28 | $1,736 | $62 |
| Triamcinolone Acetonide | 98 | $1,385 | $14 |
| Ketoconazole | 57 | $1,380 | $24 |
| Fluocinonide | 25 | $1,132 | $45 |
| Hydrocortisone | 26 | $244 | $9 |
| Cephalexin | 19 | $83 | $4 |
2021: 8 drugs
| Fluorouracil | 45 | $7,205 | $160 |
| Triamcinolone Acetonide | 70 | $1,175 | $17 |
| Doxycycline Hyclate | 25 | $1,130 | $45 |
| Metronidazole | 12 | $810 | $67 |
| Fluocinonide | 13 | $654 | $50 |
| Doxepin | 20 | $297 | $15 |
| Hydrocortisone | 17 | $80 | $5 |
| Prednisone | 11 | $34 | $3 |
2020: 4 drugs
| Fluorouracil | 42 | $7,820 | $186 |
| Triamcinolone Acetonide | 75 | $1,581 | $21 |
| Doxycycline Hyclate | 35 | $1,083 | $31 |
| Hydrocortisone | 12 | $122 | $10 |
2019: 3 drugs
| Fluorouracil | 43 | $8,481 | $197 |
| Triamcinolone Acetonide | 57 | $1,178 | $21 |
| Ketoconazole | 14 | $210 | $15 |
2018: 4 drugs
| Fluorouracil | 22 | $1,951 | $89 |
| Doxycycline Hyclate | 13 | $657 | $51 |
| Triamcinolone Acetonide | 32 | $589 | $18 |
| Hydrocortisone | 14 | $70 | $5 |
2017: 3 drugs
| Doxycycline Hyclate | 14 | $2,339 | $167 |
| Clobetasol Propionate | 12 | $1,861 | $155 |
| Triamcinolone Acetonide | 29 | $625 | $22 |
2016: 3 drugs
| Clobetasol Propionate | 17 | $3,920 | $231 |
| Doxycycline Hyclate | 16 | $2,870 | $179 |
| Triamcinolone Acetonide | 24 | $620 | $26 |
2015: 2 drugs
| Ketoconazole | 19 | $531 | $28 |
| Triamcinolone Acetonide | 15 | $212 | $14 |
2014: 1 drug
| Clobetasol Propionate | 17 | $3,347 | $197 |
Money from drug and device companies
$58 in 2024
| 2024 | 2 | 3 | None | $58 |
| 2023 | 6 | 9 | None | $218 |
| 2022 | 4 | 25 | None | $497 |
| 2021 | 1 | 1 | None | $25 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Organogenesis | Affinity | $42 | 2 payments
|
| Abbvie | Skyrizi | $16 | 1 payment
|
See all 3 published payments
| Abbvie | Meals · 2024-11-20 | Skyrizi | $16 |
| Organogenesis | Meals · 2024-11-12 | Nushield | $20 |
| Organogenesis | Meals · 2024-09-04 | Affinity | $21 |
See earlier years (2023, 2022, 2021)
2023: $218
| Genzyme | Dupixent | $69 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $40 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $39 | 2 payments
|
| Incyte | Opzelura | $26 | 1 payment
|
| Abbvie | Skyrizi | $23 | 1 payment
|
| Almirall | Klisyri | $21 | 1 payment
|
2022: $497
| Abbvie | Skyrizi | $335 | 19 payments
|
| Regeneron Healthcare Solutions | Dupixent | $84 | 3 payments
|
| Genzyme | Dupixent | $60 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $19 | 1 payment
|
2021: $25
| AbbVie | Skyrizi | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1154574853
- Licence
- CA A105136California A105136: Current · expires 2028-02-29
- Group
- University of California San Francisco · UCSF Medical Group Business Services · Roberta D Sengelmann MD Inc
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 900 Blake Wilbur Drive, Stanford, CA, 94305
- NPI first listed
- 2008-10-28
- NPI last updated
- 2021-09-28
- NPI record certified
- 2021-09-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 991 Montague Expy Ste 104, Milpitas, CA, 95035 · 525 South Dr Ste 115, Mountain View, CA, 94040 · 2420 Samaritan Dr, San Jose, CA, 95124 · 3562 Round Barn Cir Ste 320, Santa Rosa, CA, 95403 · 603 S Knickerbocker Dr, Sunnyvale, CA, 94087